Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent

Journal of Virology

Volumn 85, Issue 20, 2011, Pages 10440-10450

  Heiber, Joshua F ^a   Barber, Glen N ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; M PROTEIN; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CD49B+ NATURAL KILLER CELL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPATHOGENIC EFFECT; DRUG DOSE COMPARISON; DRUG EFFICACY; EMBRYO; FEMALE; GENE EXPRESSION; IMMUNOMODULATION; INNATE IMMUNITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; VESICULAR STOMATITIS VIRUS; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECOMBINANT PROTEINS; RODENT DISEASES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VESICULOVIRUS;

ANIMALIA; MURINAE; RHABDOVIRIDAE; VESICULAR STOMATITIS VIRUS;

EID: 80054989227     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05408-11     Document Type: Article

References (64)

1. Adkins, B., Y. Bu, E. Cepero, and R. Perez. 2000. Exclusive Th2 primary effector function in spleens but mixed Th1/Th2 function in lymph nodes of murine neonates. J. Immunol. 164:2347-2353.
2. Angelo, L. S., M. Talpaz, and R. Kurzrock. 2002. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res. 62:932-940.
3. Angiolillo, A. L., et al. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155-162.
4. Arai, K., Z. X. Liu, T. Lane, and G. Dennert. 2002. IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver. Cell Immunol. 219:48-56.
5. Balachandran, S., and G. N. Barber. 2004. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51-65.
6. Balachandran, S., et al. 1998. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 17:6888-6902.
7. Boudreau, J. E., et al. 2011. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res. 71:2497-2506.
8. Bromberg, J., and T. C. Wang. 2009. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15:79-80.
9. Brooks, C. L., and W. Gu. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15: 164-171.
10. Caelles, C., A. Helmberg, and M. Karin. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223.
11. Capo-chichi, C. D., et al. 2010. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecol. Oncol. 116:269-275.
12. Chipuk, J. E., and D. R. Green. 2006. Dissecting p53-dependent apoptosis. Cell Death Differ. 13:994-1002.
13. Cuddihy, A. R., A. H. Wong, N. W. Tam, S. Li, and A. E. Koromilas. 1999. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 18:2690-2702.
14. Dufour, J. H., et al. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168:3195-3204.
15. Enninga, J., D. E. Levy, G. Blobel, and B. M. A. Fontoura. 2002. Role of nucleoporin induction in releasing an mRNA nuclear export block. Science 295:1523-1525.
16. Faria, P. A., et al. 2005. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol. Cell 17:93-102.
17. Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76:895-904.
18. Galivo, F., et al. 2010. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther. 17:158-170.
19. Gervois, P., et al. 2004. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem. 279:16154-16160.
20. Guo, Z. S., S. H. Thorne, and D. L. Bartlett. 2008. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785:217-231.
21. Hao, M., et al. 1996. Mutation of phosphoserine 389 affects p53 function in vivo. J. Biol. Chem. 271:29380-29385.
22. He, L., et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134.
23. Heinrich, P. C., I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334:297-314.
24. Hinrichs, C., et al. 2009. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. U. S. A. 106:17469-17474.
25. Hod, E. A., et al. 2008. Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions. Blood 112:891-894.
26. Horvath, M. M., X. Wang, M. A. Resnick, and D. A. Bell. 2007. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis. PLoS Genet. 3:e127.
27. Huang, C., W. Y. Ma, A. Maxiner, Y. Sun, and Z. Dong. 1999. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 274:12229-12235.
28. Hussain, S. P., and C. C. Harris. 2006. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. J. Nippon Med. Sch. 73:54-64.
29. Kannan, K., et al. 2001. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20:2225-2234.
30. Kato, H., et al. 2005. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19-28.
31. Kawai, T., et al. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6:981-988.
32. Komarova, E. A., et al. 2005. p53 is a suppressor of inflammatory response in mice. FASEB J. 19:1030-1032.
33. Kruse, J., and W. Gu. 2009. Modes of p53 regulation. Cell 137:609-622.
34. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92:4477-4481.
35. Li, H., K.-W. Peng, D. Dingli, R. A. Kratzke, and S. J. Russell. 2010. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 17:550-558.
36. Meek, D. W. 1999. Mechanisms of switching on p53: a role for covalent modification? Oncogene 18:7666-7675.
37. Meek, D. W. 1998. Multisite phosphorylation and the integration of stress signals at p53. Cell Signal. 10:159-166.
38. Melchior, F., and L. Hengst. 2002. SUMO-1 and p53. Cell Cycle 1:245-249.
39. Munoz-Fontela, C., et al. 2005. Resistance to viral infection of super p53 mice. Oncogene 24:3059-3062.
40. Muñoz-Fontela, C., et al. 2008. Transcriptional role of p53 in interferonmediated antiviral immunity. J. Exp. Med. 205:1929-1938.
41. Nanni, P., C. de Giovanni, P. L. Lollini, G. Nicoletti, and G. Prodi. 1983. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis 1:373-380.
42. Nguyên, T. L.-A., et al. 2008. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U. S. A. 105:14981-14986.
43. Nie, C. Q., et al. 2009. IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog. 5:e1000369.
44. Obuchi, M., M. Fernandez, and G. N. Barber. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77:8843-8856.
45. Porosnicu, M., A. Mian, and G. N. Barber. 2003. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res. 63:8366-8376.
46. Ramsburg, E., et al. 2005. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced Tcell responses and is highly attenuated for replication in animals. J. Virol. 79:15043-15053.
47. Reiss, C. S., I. V. Plakhov, and T. Komatsu. 1998. Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann. N. Y. Acad. Sci. 855:751-761.
48. Roberts, M. S., R. M. Lorence, W. S. Groene, and M. K. Bamat. 2006. Naturally oncolytic viruses. Curr. Opin. Mol. Ther. 8:314-321.
49. Saloura, V., et al. 2010. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum. Gene Ther. 21:51-64.
50. Santhanam, U., A. Ray, and P. B. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. U. S. A. 88:7605-7609.
51. She, Q. B., N. Chen, and Z. Dong. 2000. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J. Biol. Chem. 275: 20444-20449.
52. Shieh, S. Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
53. Shiio, Y., T. Yamamoto, and N. Yamaguchi. 1992. Negative regulation of Rb expression by the p53 gene product. Proc. Natl. Acad. Sci. U. S. A. 89:5206-5210.
54. Suzuki, H. I., et al. 2009. Modulation of microRNA processing by p53. Nature 460:529-533.
55. Takaoka, A., et al. 2003. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516-523.
56. Taura, M., et al. 2008. p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol. Cell. Biol. 28:6557-6567.
57. Thomsen, A. R., et al. 1997. Cooperation of B cells and T cells is required for survival of mice infected with vesicular stomatitis virus. Int. Immunol. 9:1757-1766.
58. Venkataraman, T., et al. 2007. Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. J. Immunol. 178:6444-6455.
59. von Kobbe, C., et al. 2000. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol. Cell 6:1243-1252.
60. Wongthida, P., et al. 2011. Activating systemic T cell immunity against self tumor antigens to support oncolytic virotherapy with VSV. Hum. Gene Ther. doi:10.1089/hum.2010.216.
61. Wu, L., et al. 2008. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum. Gene Ther. 19:635-647.
62. Xue, W., et al. 2007. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445:656-660.
63. Yang, Q., et al. 2010. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18:258-267.
64. Zhang, F., and S. Sriram. 2009. Identification and characterization of the interferon-beta-mediated p53 signal pathway in human peripheral blood mononuclear cells. Immunology 128:e905-e918.